BioCorRx Forms Subsidiary

BioCorRx, developer of the BioCorRx Recovery Program, a medication-assisted treatment (MAT) program, has formed a new subsidiary, BioCorRx Pharmaceuticals, in conjunction with the company’s development, commercialization and license agreement with TheraKine for exclusive worldwide rights, licenses and sublicensing to patented and patent pending TheraKine technology for sustained release naltrexone delivery.

BioCorRx Pharmaceuticals will focus on development and commercialization activities of the technology for an injectable naltrexone with the potential to deliver therapeutic levels of naltrexone for 30 days subcutaneously and/or for a few months intramuscularly. The subsidiary will also be used to do further work on the company’s naltrexone implant product(s).

“Moving forward with our development of a new injectable naltrexone product and R&D initiative involving the implant, it made strategic sense to create a new subsidiary to handle these initiatives, separate from our operational company which will continue distributing the BioCorRx Recovery Program,” said Brady Granier, chief executive officer, BioCorRx.